The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 20, 2018
Filed:
Sep. 12, 2013
Applicant:
Netris Pharma, Lyons, FR;
Inventors:
Assignee:
NETRIS PHARMA, Lyons, FR;
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 31/513 (2006.01); A61K 31/704 (2006.01); A61K 45/06 (2006.01); A61K 31/337 (2006.01); A61K 31/713 (2006.01); A61K 33/24 (2006.01); A61K 31/282 (2006.01); A61K 31/7105 (2006.01); A61K 31/395 (2006.01); A61K 38/17 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/395 (2013.01); A61K 31/513 (2013.01); A61K 31/704 (2013.01); A61K 31/713 (2013.01); A61K 31/7105 (2013.01); A61K 33/24 (2013.01); A61K 38/177 (2013.01); A61K 39/395 (2013.01); A61K 45/06 (2013.01); C07K 2319/30 (2013.01);
Abstract
Pharmaceutical composition comprising a chemotherapeutic drug and a netrin-1 interfering drug or a vector capable of expressing a netrin-1 interfering drug in vivo, in a pharmaceutically acceptable carrier or vehicle. The chemotherapeutic drug is selected from those able to induce over expression of netrin-1 in cancer cells. The combination is associated with synergic anti-cancer effect.